Buying Chinook will add a pair of late-stage programs to Novartis's IgAN portfolio which is currently headed by iptacopan but the proposed deal could attract the attention of the FTC.

The maker of Cabometyx wants to expand its oncology pipeline via deal-making but is wary of the high attrition rate in cancer. Option deals with Cybrexa and Sairopa may avoid some of that risk.

Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.

Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.